Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
67,974,787
-
Share change
-
+870,211
-
Total reported value
-
$2,304,237,493
-
Put/Call ratio
-
81%
-
Price per share
-
$33.93
-
Number of holders
-
164
-
Value change
-
+$32,399,854
-
Number of buys
-
68
-
Number of sells
-
93
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2021
As of 31 Mar 2021,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
164 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,974,787 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, WASATCH ADVISORS INC, BlackRock Inc., Bellevue Group AG, MARSHALL WACE, LLP, LORD, ABBETT & CO. LLC, CITADEL ADVISORS LLC, STATE STREET CORP, and SAMLYN CAPITAL, LLC.
This page lists
164
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.